KR20120029553A - Preventing and treating composition for obesity comprising silymarin or its salts as an active ingredient - Google Patents

Abstract

PURPOSE: A composition containing silymarin or salt thereof is provided to suppress differentiation of adipocytes and to reduce body fat. CONSTITUTION: A composition for preventing and treating obesity contains 0.1-10 wt% of silymarin or salt thereof as an active ingredient. The composition is a pharmaceutical composition or food additive composition. A method for manufacturing the composition for preventing and treating obesity contains silymarin or salt thereof as an active ingredient. The composition is manufactured in the form of a tablet, sugar-coated tablet, soft and hard capsule, solution, emulsion, or suspension.

Description

PREVENTING AND TREATING COMPOSITION FOR OBESITY COMPRISING SILYMARIN OR ITS SALTS AS AN ACTIVE INGREDIENT}

The present invention relates to a composition for preventing and treating obesity, and more particularly, it is a natural material that can be extracted from thistle and is safe without toxicity, and has an excellent effect of inhibiting differentiation in fat cells, increasing fatty acid oxidation, The present invention relates to a composition useful for the treatment of obesity and related diseases by reducing the accumulation of fat in tissues to improve the level of fat in the liver and adipose tissue due to a high fat diet to inhibit obesity.

Obesity is not a serious problem of obesity itself, but metabolic diseases such as diabetes, arteriosclerosis, cardiovascular disease and hyperlipidemia, which are caused by it, are a serious social problem. According to the latest data released by the Ministry of Health, Welfare and Family Affairs, the amount of physical activity of our people has decreased and obesity-related diseases have increased in recent two years. Obesity among those with BMI 25 or higher increased 1.5% to 36.2%, especially in men (up 11.1% over 10 years). Obesity is primarily caused by excess energy stored in the body in the form of triglycerides and other fat metabolites, and is caused by comprehensive metabolic abnormalities caused by the imbalance of energy metabolism. Approaches are needed in various aspects, including adipocyte differentiation, fat synthesis and degradation, and heat generation reactions. The prevalence of obesity in children and adolescents also increased, and hyperlipidemia associated with obesity continued to increase, increasing by 2.7% to 10.8%. Therefore, anti-obesity material development research has been carried out on cytokine signaling 3 suppressor that induces the resistance of leptin, an appetite suppressant, and cannabinoid receptor 1 antagonist, which is involved in regulating food intake in the hypothalamus. β3-adrenergic with weight loss by inhibiting appetite such as cannabinoid receptor 1 antagonist, neuropeptide Y antagonist that stimulates appetite Increasing energy consumption, such as β3-adrenergic receptor agonist and PPARδ, which is involved in promoting energy consumption through overexpression of UCP, is aimed at weight loss.

Since the drugs developed for the treatment of obesity have serious side effects compared to the effects, the anti-obesity effect is high and can be used in a small dose. Therefore, there is an urgent need for the development of a substance having a new mechanism of action of natural materials with relatively few side effects.

The present invention has been made to solve the problems of the prior art as described above, the object is derived from natural substances, there is no toxicity, excellent effect of inhibiting differentiation in fat cells, increase fatty acid oxidation, It is to provide a composition useful in the treatment of obesity and related diseases by reducing the accumulation of fat in the tissue to improve the level of fat in the liver and adipose tissue by high fat diet to suppress obesity.

The technical problem of the present invention as described above is achieved by the following means.

(1) A composition for preventing and treating obesity, containing silymarin or a salt thereof as an active ingredient.

(2) The method according to claim 1,

The composition is a composition for preventing and treating obesity, characterized in that the pharmaceutical composition.

(3) The method according to claim 1,

The composition is a composition for preventing and treating obesity, characterized in that the composition for food additives.

(4) The method according to 1,

Silymarin or a salt thereof is a composition for preventing and treating obesity, characterized in that added 0.1 to 10% by weight.

(5) A food composition for the prevention and treatment of obesity, containing silymarin or a salt thereof as an active ingredient.

(6) a method for producing obesity prevention and treatment composition comprising the step of adding silymarin or its salt as an active ingredient.

The obesity prevention and treatment composition according to the present invention is derived from natural substances, has an excellent effect of inhibiting differentiation in adipocytes, increases fatty acid oxidation, and decreases accumulation of fat in tissues, thereby reducing liver and fat by high fat diet. Improving fat levels in tissues to inhibit obesity provides compositions useful for the treatment of obesity and related diseases.

1 is an oil red O staining test results to observe the effect of inhibiting the adipocyte differentiation of silymarin in 3T3-L1 adipocytes.
Figure 2 is a Western blot experiment conducted to observe the inhibitory effect of silymarin adipocyte differentiation in 3T3-L1 adipocytes.
Figure 3 is the result of measuring the effect on the weight change of silymarin in the mouse.
4 is a staining result of epididymal adipose tissue obtained by feeding silymarin to mice according to the present invention.

The present invention provides a composition for preventing and treating obesity containing silymarin or a salt thereof as an active ingredient.

Hereinafter, the content of the present invention will be described in detail.

Silymarin is a flavonolignan mixture, which collectively refers to three compounds: silibium marianum (aka Milk Thistle), known as thistle. Extracted.

According to the present invention, the silymarin has an excellent effect of inhibiting differentiation in adipocytes, increases fatty acid oxidation, decreases the accumulation of fat in tissues, and improves fat levels in liver and adipose tissue by high-fat diet and obesity. It has been found to inhibit and is useful as an active ingredient of a composition for the treatment of obesity and related diseases.

Obesity prevention and treatment compositions according to the invention is characterized in that the silymarin or its salt is contained 0.1 to 10% by weight relative to the total weight. If it is added less than 0.1% by weight it is difficult to expect anti-obesity activity, if it exceeds 10% by weight is difficult to expect the synergistic effect due to excess and is not preferable because of side effects.

As the salt of silymarin according to the present invention, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. Acid addition salts can be prepared by conventional methods, for example, by dissolving a compound in an excess of aqueous acid solution and precipitating the salt using a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Equal molar amounts of the compound and acid or alcohol (eg, glycol monomethylether) in water can be heated and the mixture can then be evaporated to dryness or the precipitated salts can be suction filtered.

In this case, organic acids and inorganic acids may be used as the free acid, hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc. may be used as the inorganic acid, and methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, Citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, Carbonic acid, vanillic acid, hydroiodic acid and the like can be used.

Bases can also be used to make pharmacologically acceptable metal salts. An alkali metal or alkaline earth metal salt is obtained by, for example, dissolving a compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and then evaporating and drying the filtrate. At this time, as the metal salt, it is particularly suitable to prepare sodium, potassium or calcium salts, and the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).

The composition for preventing and treating obesity according to the present invention may be administered orally as a pharmaceutical composition in the form of tablets, lacquered tablets, sugar coated tablets, hard and soft capsules, solutions, emulsions or suspensions. Formulations of this type can also be administered parenterally. It may also be administered rectally, for example in the form of suppositories, or parenterally in the form of injections. The active ingredients may be formulated in a form containing all of the active ingredients in the above oral or parenteral dosage forms, or may be administered separately in a special combination of single substances that can be administered together or sequentially. To prepare tablets, lacquered tablets, sugar coated tablets and capsules, pharmaceutically inert, inorganic or organic excipients may be added for the formulation of the present invention. Such excipients include lactose, corn starch or derivatives thereof, talc, stearic acid or salts thereof. Suitable excipients for the capsules include vegetable oils, waxes, fats, semisolid or liquid polyols. Suitable excipients for preparing solutions and syrups are, for example, water, polyols, sucrose, invert sugar glucose and the like. Suitable excipients for injection include water, alcohols, glycerol, vegetable oils. Suitable excipients for suppositories include natural or hardened oils, waxes, fats, semi-liquid or liquid polyols.

The formulations according to the invention may also further contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, coloring agents, flavoring agents, osmotic agents, buffers, coatings and / or antioxidants as necessary.

Preferred dosages of silymarin or salts thereof in the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. In the case of the present invention, it is preferable to administer 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day, and may be administered once a day or divided into several times.

In addition, the present invention includes a food composition comprising the silymarin or a salt thereof. Examples of the food to which the compound can be added include various foods, beverages, gums, teas, vitamin complexes, and health supplements. At this time, the amount of the compound in the food or beverage is generally in the case of the dietary supplement composition of the present invention can be added to 0.1 to 20% by weight, preferably 1 to 15% by weight of the total food weight, It can be added at a ratio of 1 to 25 g, preferably 2 to 15 g, based on 100 ml. The health beverage composition of the present invention is not particularly limited to the liquid component except for containing the compounds as essential ingredients in the ratios indicated, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have.

In addition to the above, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the food compositions of the present invention may contain fruit flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 30 parts by weight per 100 parts by weight of the food composition of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples, but these Examples are only presented to aid the understanding of the present invention, and the scope of the present invention should not be construed as being limited thereto.

Example 1 Adipocyte Differentiation Inhibitory Activity

Induction of 3T3-L1 Culture and Differentiation

Mouse Embryo 3T3-L1 cell line cell line purchased from American Type Culture Collection (ATCC) in 2.5 × 10 ⁵ cells / ml in Dulbecco's modified Eagle's medium (DMEM) medium with 10% bovine serum and 1% penicillin / streptomycin Incubated for 72 hours by floating to concentration and incubated in a 37 ℃ CO ₂ incubator to be confluent (confluent). Differentiation medium (10% FBS, 1% penicillin / streptomycin, 5 μg / ml insulin, 1 μM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine) was incubated for 48 hours. At this time, the sample (dissolved in DMSO) was treated together. After 48 hours of incubation, the cells were incubated for 48 hours in 10% FBS DMEM medium containing 5 μg / ml insulin to promote differentiation into adipocytes. Thereafter, medium was exchanged twice with 48% intervals in 10% FBS DMEM to induce differentiation into adipocytes.

Oil Red O Dyeing

For staining of the lipid droplets of the differentiated adipocytes, staining was performed with Oil red O, which reacts specifically with the fat. After removing the medium, 1 ml of 10% formalin was treated once for 5 minutes, and then fixed with 1 ml of fresh 10% formalin for 1 hour. Each well was completely dried after washing with 60% isopropanol. Oil red O dye (6 parts Oil red O stock, 4 parts dH ₂ O) was treated for 10 minutes and washed four times with distilled water. As a result of observing the differentiated cells under the microscope, it was confirmed that the differentiation was suppressed in the cells treated with silymarin. After the dH ₂ O was discarded, the wells were completely dried, and treated with 100% isopropanol for 10 minutes for elution of oil-bound O bound with fat, and the absorbance was measured at 490 nm.

As a result, as shown in Figure 1 it was confirmed that as the concentration of silymarin increases the differentiation of adipocytes is suppressed.

Western blotting

Adipocytes Tris pH 8.0, 150 mM Tris NaCl, 0.02% sodium azide, 0.2% SDS, PMSF (phenylmethylsulfonyl fluoride) 100 ug / ml, aprotinin 50 ug / ml, NP-40 1%, NaF 100 After homogenizing 200 μl of RIPA buffer composed of mM, sodium deoxycholate 0.5%, EDTA 0.5 mM, and EGTA 0.1 mM, the supernatant was separated by centrifugation at 13,000 rpm for 20 minutes. The supernatant was transferred to a new tube, the protein was quantified, electrophoresed with SDS-polyacrylamide gel at a constant concentration of 20 μg, and then Western blotting. The electrophoresis gel was equilibrated with about 50 ml of transfer solution for 30 minutes. The PDVF membrane was also cut to an appropriate size and then immersed in buffer as well as gel and allowed to equilibrate for 30 minutes. The western blot cassette was placed in a container containing a transfer buffer, and on top of it was placed a deckron sponge and two Whatman 3MM filter papers soaked in the transfer buffer. Gels equilibrated with transfer buffer solution were carefully placed on Whatman 3MM filter paper to avoid bubbles. The membrane equilibrated with the transfer buffer solution on the gel was carefully placed to prevent the formation of bubbles, and two sheets of filter paper and a decron sponge were placed thereon. The cassette was securely fixed to prevent bubbles and the clips were tightened to prevent both cassettes from falling out. After transferring the installed cassette to the blotting chamber, insert the transfer buffer solution to the marked part so that the membrane in the cassette is sufficiently submerged. Install the electrode so that the membrane side is the anode and the gel side is the cathode. Transferred for time. The protein-transferred membrane was immersed in a TBST solution containing 1% bovine serum albumin and left at 4 ° C. for 12 hours to block the non-protein-bound portion of the membrane. The buffer used for blocking was removed and the membrane washed three times for 10 minutes with TBST solution. Primary antibodies (C / EBPa, PPARγ, β-actin) diluted to appropriate concentrations using TBST buffer solution were added so that the membrane was sufficiently submerged and allowed to react at 4 ° C for 12 hours. The membrane was washed three times for 10 minutes with TBST solution. Anti-racket-HRP, appropriately diluted with TBST solution, was reacted for 2 hours at room temperature. The membrane was washed three times for 10 minutes with TBST solution. Then, the film was developed by the ECL reaction in the dark room to check the band.

As shown in FIG. 2, silymarin may increase fatty acid oxidation and reduce the accumulation of fat in tissues, thereby improving the fat level of liver tissue by high-fat diet and suppressing obesity.

Experimental Example 2 Animal Experiment

Animal breeding and diet composition

Four-week-old male C57 BL / 6J was adapted to the environment for one week with solid blended feed. Thereafter, each experimental group was randomly divided into three groups of 10 animals, and fed with an experimental diet for 8 weeks. The experimental diet was prepared based on the AIN-76 diet, and hyperlipidemia and obesity were induced by adding 15% Lard and 0.25% cholesterol. The experimental group was divided into three groups: normal group, high fat diet control group, and silymarin addition group. In order to evaluate the efficacy of candidates on obesity induced by high-fat diet, 8-week-high diet of silymarin added to C57 / BL6j mice resulted in significant weight gain due to high-fat diet as shown in FIG. It was reduced by the enemy.

Histological examination

Some of the epididymal tissues extracted for morphological observation of adipose tissue cells were extracted and fixed in 10% formaldehyde solution and embedded in paraffin permeation after dehydration. The thin slicer was cut to a thickness of about 4 μm, stained with hematoxylin-eosin (HE), cleared with xylene, sealed, and observed with an optical microscope.

As a result of staining of the epididymal adipose tissue, as shown in FIG. 4, the size of the adipose tissue was significantly increased in the control group ingesting a high fat diet as compared to the adipose tissue of the normal group. It has been shown that the size of fat cells decreases.

As we have seen through the above experiment. Excellent effect of inhibiting differentiation in adipocytes according to the present invention, increases fatty acid oxidation, decreases the accumulation of fat in tissues, improves the fat level in liver and adipose tissue by high fat diet, inhibits obesity by inhibiting obesity and It can be found that it is useful for the treatment of diseases related thereto.

As described above, it has been described with reference to a preferred embodiment of the present invention, but those skilled in the art various modifications and changes of the present invention without departing from the spirit and scope of the invention described in the claims below I can understand that you can.

Claims (6)

Obesity prevention and treatment composition containing silymarin or a salt thereof as an active ingredient. The method of claim 1,
The composition is a composition for preventing and treating obesity, characterized in that the pharmaceutical composition. The method of claim 1,
The composition is a composition for preventing and treating obesity, characterized in that the composition for food additives. The method of claim 1,
Silymarin or a salt thereof is a composition for preventing and treating obesity, characterized in that the addition of 0.1 to 10% by weight. A food composition for preventing and treating obesity, containing silymarin or a salt thereof as an active ingredient. Method for producing a composition for preventing and treating obesity, comprising the step of adding silymarin or a salt thereof as an active ingredient.

Images